{"filing":{"accession_number":"0001104659-26-084242","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"tm2620677d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926084242/tm2620677d1_8k.htm"},"events":[{"id":18401,"run_id":16541,"accession_number":"0001104659-26-084242","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Stockholders approved four substantive proposals at a Special Meeting: approval of warrant issuances from a registered direct offering and private placement, authorization to increase authorized common shares from 260 million to 600 million, and authorization for a reverse stock split at a 1-for-10 to 1-for-50 ratio. The certified voting results, including vote counts for, against, abstentions, and broker non-votes for each matter, are disclosed.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17199,"accession_number":"0001104659-26-084242","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports a stockholder-approved amendment to the Company's Restated Certificate of Incorporation increasing authorized common shares from 260 million to 600 million. While a routine governance matter, the substantial increase in authorized shares (130% increase) is material to investors as it expands the Company's capacity for future equity issuances, dilution, and capital-raising activities, affecting shareholder interests and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:39.298282+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17200,"accession_number":"0001104659-26-084242","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the certified results of a Special Meeting of stockholders, including voting tallies on four substantive proposals: approval of warrant issuances from a registered direct offering and private placement (Proposals 1(a) and 1(b)), authorization to increase authorized shares from 260 million to 600 million (Proposal 2), and authorization for a reverse stock split at a 1-for-10 to 1-for-50 ratio (Proposal 3). The disclosure includes vote counts for, against, abstentions, and broker non-votes for each matter, which is the hallmark of shareholder_vote_results. These outcomes are material to investors as they enable significant dilutive issuances and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:39.298282+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17199,"accession_number":"0001104659-26-084242","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports a stockholder-approved amendment to the Company's Restated Certificate of Incorporation increasing authorized common shares from 260 million to 600 million. While a routine governance matter, the substantial increase in authorized shares (130% increase) is material to investors as it expands the Company's capacity for future equity issuances, dilution, and capital-raising activities, affecting shareholder interests and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:39.298282+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-07-16"},{"id":17200,"accession_number":"0001104659-26-084242","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the certified results of a Special Meeting of stockholders, including voting tallies on four substantive proposals: approval of warrant issuances from a registered direct offering and private placement (Proposals 1(a) and 1(b)), authorization to increase authorized shares from 260 million to 600 million (Proposal 2), and authorization for a reverse stock split at a 1-for-10 to 1-for-50 ratio (Proposal 3). The disclosure includes vote counts for, against, abstentions, and broker non-votes for each matter, which is the hallmark of shareholder_vote_results. These outcomes are material to investors as they enable significant dilutive issuances and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:39.298282+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-07-16"}]}